Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

Merck (NYSE:MRK) received Health Canada approval for ENFLONSIA, its RSV preventive therapy for infants. The authorization ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Tuesday before the bell. Here’s what you need ...

Merck (NYSE:MRK) has received Health Canada approval for ENFLONSIA (clesrovimab), a monoclonal antibody for RSV prevention in newborns and infants. The product is indicated for the prevention of lower ...

Merck & Co., Inc. stock reached a 52-week high, closing at $112.91. This milestone reflects a significant upward trend for the pharmaceutical giant, with its stock price appreciating by 13.07% over ...

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

The latest market snapshot at Thursday morning reveals Merck & Co shares up by 1.21%, trading at $108.19. About Merck & Co. Merck makes pharmaceutical products to treat several co ...

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter ...

Merck has increased its dividend for 14 consecutive years. Its 10-year dividend growth rate of 5.4% is only decent. Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY ...

It was revealed in a recent SEC filing that Chirfi Guindo, Chief Marketing Officer at Merck & Co (NYSE: MRK) made a ...